RESEARCH: COMPLICATIONS

Body mass index, estimated glucose disposal rate and vascular complications in type 1 diabetes: Beyond glycated haemoglobin

Rebecca Helliwell1 | Harriet Warnes1 | Noppadol Kietsiriroje2,3 | Matthew Campbell4 | Rebecca Birch5 | Sam M. Pearson1,2 | Ramzi A. Ajjan2

1School of Medicine, University of Leeds, Leeds, UK
2Leeds Institute of Cardiovascular and Metabolic Medicine, Faculty of Medicine and Health, University of Leeds, Leeds, UK
3Endocrinology and Metabolism Unit, Internal Medicine Department, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand
4Faculty of Health Sciences and Wellbeing, University of Sunderland, Sunderland, UK
5Division of Pathology and Data analytics, University of Leeds, Leeds, UK

Correspondence
Ramzi A. Ajjan, Leeds Institute of Cardiovascular and Metabolic Medicine Research, LIGHT Laboratories, Clarendon Way, LS2 9DA Leeds, UK
R.ajjan@leeds.ac.uk

Funding information
Prince of Songkla University

Abstract

Aims: To understand the relationship between insulin resistance (IR), assessed as estimated glucose disposal rate (eGDR), and microvascular/macrovascular complications in people with type 1 diabetes.

Materials and methods: Individuals with a confirmed diagnosis of type 1 diabetes were included in this cross-sectional study. BMI was categorised into normal weight (18.0–24.9 kg m−2), overweight (25.0–29.9 kg m−2) and obese groups (≥30.0 kg m−2). We categorised eGDR into four groups: eGDR >8, 6–7.9, 4–5.9 and <4 mg kg−1 min−1. Multiple logistic regression was used to identify associations with vascular complications, after adjusting for relevant confounders.

Results: A total of 2151 individuals with type 1 diabetes were studied. Median [interquartile range (IQR)] age was 41.0 [29.0, 55.0] with diabetes duration of 20.0 [11, 31] years. Odds ratio (OR) for retinopathy and nephropathy in obese compared with normal weight individuals was 1.64 (95% CI: 1.24–2.19; p = 0.001) and 1.62 (95% CI: 1.10–2.39; p = 0.015), while the association with cardiovascular disease just failed to reach statistical significance (OR 1.66 [95% CI: 0.97–2.86; p = 0.066]). Comparing individuals with eGDR ≥8 mg kg−1 min−1 and <4 mg kg−1 min−1 showed OR for retinopathy, nephropathy and macrovascular disease of 4.84 (95% CI: 3.36–6.97; p < 0.001), 8.35 (95% CI: 4.86–14.34; p < 0.001) and 13.22 (95% CI: 3.10–56.38; p < 0.001), respectively. Individuals with the highest eGDR category (≥8 mg kg−1 min−1) had the lowest complication rates irrespective of HbA1c levels.

Conclusions: Obesity is prevalent in type 1 diabetes and diabetes complications are not only related to glucose control. IR, assessed as eGDR, is strongly associated with both microvascular and macrovascular complications, regardless of HbA1c levels.

KEYWORDS

insulin resistance, obesity, type 1 diabetes, complications
**INTRODUCTION**

According to the National Institute for Clinical Excellence, type 1 diabetes affects over 370,000 adults in the United Kingdom\(^2\) and more than 1.6 million people are living with the condition in the United States.\(^2\) Based largely upon the findings of the Diabetes Control and Complications Trial,\(^3\) various guidelines recommend intensive insulin regimes to achieve a HbA1c <6.5% or <7.0% (<48 or <53 mmol/mol), unless this target cannot be achieved due to disabling hypoglycaemia.\(^4\) Obesity and insulin resistance (IR) are increasing in type 1 diabetes, partly related to lifestyle choices but also secondary to the condition itself. Subcutaneous insulin administration can induce peripheral IR both directly \(^5\)-\(^7\) and indirectly through weight gain\(^8\) and treatment of repeated hypoglycaemia.\(^9\) Consequently, this can lead to the challenging clinical scenario of escalating insulin doses, further weight gain and increasing IR creating a vicious cycle. The weight gain can have detrimental vascular effects through the development of an inflammatory and thrombotic milieu, typically associated with insulin-resistant states.\(^10\)-\(^12\)

It has been proposed that people with type 1 diabetes and IR constitute a clinical entity, termed ‘double diabetes (DD).’\(^13\) However, the exact definition of this group has been problematic with early studies labelling those with autoimmune diabetes and a family history of type 2 as having DD.\(^14\),\(^15\) The definition of DD was subsequently refined to include type 1 diabetes individuals with features of the metabolic syndrome, a subpopulation that showed adverse clinical outcome compared with the rest of type 1 diabetes group.\(^16\)

Estimated glucose disposal rate (eGDR) is a marker of IR, derived from data using euglycaemic–hyperinsulinenic clamps in 24 individuals with type 1 diabetes.\(^17\) This is calculated according to a formula that uses standard clinical measures including waist–hip ratio (alternatively, waist circumference or BMI), HbA1c and presence of hypertension. The strong correlation between eGDR and IR, using the gold standard clamp techniques, indicates this is a valuable marker to identify the presence of DD in those with type 1 diabetes.\(^17\)-\(^19\) Previous work has demonstrated a relationship between IR and vascular complications in people with type 1 diabetes while more recent prospective work linked eGDR with cardiovascular and all-cause mortality in this cohort.\(^18\),\(^20\)-\(^26\) However, the exact contribution of eGDR and its components to risk of complications is not entirely clear, particularly in patients on modern management strategies.

We hypothesise that the risk of both microvascular disease and macrovascular complications in people with type 1 diabetes is not only determined by glycaemic control and IR has a key role. Therefore, the main aims of this study were to explore (i) relationship between obesity, assessed as BMI and diabetes-related microvascular and macrovascular complications, (ii) relationship between IR, measured as eGDR, and diabetes complications and (iii) understand the association between vascular risk factors, obesity and IR.

**METHODS**

For this study, a cross-sectional design was used with electronic patient data from November 2016 to February 2018, reviewed in Leeds Teaching Hospital Trust in England, UK. Data were collected on a single timepoint using the following inclusion criteria: (i) confirmed diagnosis of type 1 diabetes for over 1 year and current treatment with insulin. Diagnosis of type 1 diabetes was defined as being recorded in the medical records by a consultant physician or senior trainee in diabetes: (ii) availability of recent weight and height data, (iii) age over 18 years old and (iv) BMI \(\geq 18.0\) kg/m\(^2\). Exclusion criteria were as follows: (i) diabetes aetiology is not confirmed or in doubt and (ii) having an established diagnosis of an eating disorder or a disorder related to body dysmorphia accompanied with a low BMI (<18.0 kg/m\(^2\)). The study was classified as an audit and no ethical approval was deemed necessary as per local protocols. All data were anonymised before analysis.

**Outcome definitions**

All outcomes were recorded from the most recent clinical information within the past 2 years preceding clinic attendance. BMI was categorised as healthy weight (18–24.9 kg/m\(^2\)), overweight (25–30 kg/m\(^2\)) and obese (>30 kg/m\(^2\)). eGDR was used as a measure of IR and calculated using the formula; eGDR-BMI = 19.02 − (0.22 × BMI, kg m\(^{-2}\)) − (3.26 × hypertension, presence) − (0.61 × HbA\(_1c\), %), whereby the presence of hypertension was defined by the actual blood pressures \(\geq 140/90\) mmHg or current use of any anti-hypertensive agents.\(^17\),\(^19\) eGDR was categorised into four categories.
Retinopathy was defined as present if the observed abnormalities were more than simple background grade R1 alterations (R1 = mild non-proliferative changes and absence of macular disease) in at least one eye using retinal photography. Nephropathy was defined as estimated glomerular filtration rate < 60 ml min⁻¹ m⁻² and/or history of persistent albuminuria. Persistent albuminuria was defined as Urine Albumin:Creatinine Ratio > 3.0 mg mmol⁻¹ on more than one occasion. Cardiovascular disease was defined as a history of myocardial infarction, angina, coronary revascularisation, documented ischaemic heart disease, stroke or transient ischaemic attacks.

### 2.2 Statistical analysis

Descriptive data were presented in mean ± SD, median [IQR] or number (%). One-way ANOVA or Kruskal–Wallis and Chi-square tests were used to compare baseline characteristics among BMI categories for continuous and categorical variables, respectively. Generalised linear regression was used to estimate the mean difference of blood pressure or lipid parameters among BMI category with adjustment for age, sex, diabetes duration, the use of antihypertensive or statin (where relevant), and HbA1c. To estimate mean differences of lipid parameters among eGDR category, the mean differences were estimated for the same confounders as for BMI except for HbA1c, which is part of eGDR calculation. Multiple logistic regression was used to evaluate the association between presence of microvascular or macrovascular complications and BMI or eGDR categories. BMI and eGDR categories were presented as crude and adjusted odd ratio (OR) with age, gender, diabetes duration and HbA1c adjusted for BMI category; and age, gender and diabetes duration adjusted for eGDR category. Further adjustment for treatment effect including statins, anti-hypertensives and adjunct oral hypoglycaemic agents was carried out for both BMI and eGDR categories. We added clinically relevant variables to the models while avoiding ‘overfitting’. We also avoided including any variable with missing data >10% into adjusted models. The percentage of missing data of each variable is presented in Table 1. SPSS version 25.0 (IBM Incorporation) was used for all analyses.

Given that HbA1c, BMI and presence of hypertension are part of eGDR calculation, adjustments for these variables were not made when analysing the association between eGDR and complications. A similar methodology has been used in the past for the analysis of eGDR.²⁷

### 3 RESULTS

A total of 2375 individuals were identified for the study of whom 2151 met inclusion criteria. Reasons for exclusion are shown in Figure 1. Of 2151 individuals, median age was 41.0 [29.0, 55.0] years, 53.8% were men, mean BMI was 27.0 ± 4.9 kg m⁻², median duration of diabetes was 20.0 (11, 31) years and mean HbA1c was 69.1 ± 17.5 mmol mol⁻¹. Of 2094 individuals having HbA1c data, mean eGDR was 6.31 ± 2.32 mg kg⁻¹ min⁻¹. A summary of data from the initial screening process of eligible participants is shown in Table 1.

### 3.1 Obesity, IR and diabetes-related complications

#### 3.1.1 Retinopathy

Retinopathy, defined as any change higher than retinopathy grade R1, was present in 21.3% of the study cohort. For BMI, a significant increase in OR was seen with higher BMI category in an unadjusted model. After adjustment for age, gender, HbA1c and duration of diabetes, a similar pattern was observed, although less pronounced (Figure 2). When further adjustments were made for statins, anti-hypertensives and adjuvant anti-glycaemic therapies, obese individuals still showed an increased frequency of retinal complications (adjusted OR 1.38 [95% CI: 1.02–1.87; p = 0.04]) (Table S1).

When eGDR was used instead of BMI, large differences were seen in the unadjusted model and also in the model adjusted for age, gender and diabetes duration (Figure 3). These differences also remained significant after further adjustment for therapies other than insulin (adjusted OR 2.12, 2.02 and 4.07 for eGDR 6–7.9, 4–5.9 and <4 mg kg⁻¹ min⁻¹, respectively; p < 0.001 for all) (Table S1).

#### 3.1.2 Nephropathy

Nephropathy was present in 18.6% of patients. Comparing across BMI categories, crude OR showed no difference in rates of nephropathy between normal weight and overweight groups but there was a significant increase in obese individuals (crude OR 1.93 [95% CI: 1.35–2.76; p < 0.001]). However, after adjusting for age, gender, HbA1c and diabetes duration, the degree to which obesity increased the odds was diminished (adjusted OR 1.62 (95% CI: 1.10–2.39; p = 0.015)) (Figure 2) and indeed after further adjustment to include non-insulin therapies, no significant differences were seen across BMI cohorts (Table S1).

When analysing the relationship between eGDR and nephropathy, a strong relationship was observed between falling
| Patient characteristic                      | Normal weight (n = 832) | Overweight (n = 819) | Obese (n = 500) | p value | Missing data in total (%) | Missing data by group (%) |
|--------------------------------------------|-------------------------|----------------------|-----------------|---------|---------------------------|--------------------------|
| Median age, years                          | 37.0 [26.0, 53.0]       | 43.0 [30.0, 55.0]    | 47.0 [35.0, 59.0]| <0.001  | 0                         |                          |
| Gender, men                                | 425 (51.1%)             | 485 (59.2%)          | 248 (49.6%)     | <0.001  | 0                         |                          |
| Median duration of diabetes, years         | 17.0 [9.29]             | 20.0 [11.0, 31.0]    | 24.0 [15.0, 34.0]| <0.001  | 0                         |                          |
| BMI, kg m⁻²                                 | 22.5 (1.7)              | 27.2 (1.4)           | 33.9 (3.7)      | <0.001  | 0                         |                          |
| cGDR, mg kg⁻¹ min⁻¹                        | 7.66 (1.83)             | 6.27 (1.89)          | 4.15 (2.03)     | <0.001  | 2.6                       | 3.1, 2.6, 2.0            |
| SBP, mmHg                                  | 128.8 (16.9)            | 133.7 (16.7)         | 138.4 (17.7)    | <0.001  | 0.5                       | 0.7, 0.5, 0.2            |
| DBP, mmHg                                  | 75.9 (9.4)              | 77.4 (8.7)           | 78.9 (9.7)      | <0.001  | 0.6                       | 0.8, 0.6, 0.2            |
| Presence of HTN, no.                       | 303 (36.7%)             | 421 (51.7%)          | 335 (67.3%)     | <0.001  | 0.6                       | 0.7, 0.6, 0.4            |
| Number of antihypertensives, no.           |                         |                      |                 | <0.001  | 0.4                       | 0.1, 0.5, 0.8            |
| None                                       | 635 (76.4%)             | 535 (65.6%)          | 241 (48.6%)     |         |                           |                          |
| 1 agent                                    | 127 (15.3%)             | 172 (21.1%)          | 123 (24.8%)     |         |                           |                          |
| 2 agents                                   | 47 (5.7%)               | 77 (9.4%)            | 94 (19.0%)      | <0.001  | 0.4                       | 0.1, 0.5, 0.8            |
| ≥3 agents                                  | 22 (2.6%)               | 31 (3.8%)            | 38 (7.8%)       | <0.001  | 0.4                       | 0.1, 0.5, 0.8            |
| eGFR, ml min⁻¹ m⁻²                         |                         |                      |                 | <0.001  | 10.1                      | 9.4, 11.0, 8.4           |
| >90                                        | 649 (86.5%)             | 578 (79.7%)          | 350 (76.4%)     |         |                           |                          |
| 60–89.9                                    | 70 (10.5%)              | 116 (16.0%)          | 75 (16.4%)      |         |                           |                          |
| 30–59.9                                    | 11 (1.5%)               | 24 (3.3%)            | 29 (6.3%)       |         |                           |                          |
| 15–29.9                                    | 6 (0.8%)                | 4 (0.6%)             | 2 (0.4%)        |         |                           |                          |
| <15                                        | 5 (0.7%)                | 3 (0.4%)             | 2 (0.4%)        | <0.001  | 0.4                       | 0.1, 0.5, 0.8            |
| Mode of insulin delivery                   |                         |                      |                 | 0.838   | 0                         | 0                         |
| MDI                                        | 64 (77.0%)              | 639 (78.0%)          | 398 (79.6%)     |         |                           |                          |
| CSII                                       | 126 (15.1%)             | 120 (14.7%)          | 65 (13.0%)      |         |                           |                          |
| Mixed insulin                              | 65 (7.8%)               | 60 (7.3%)            | 37 (7.4%)       |         |                           |                          |
| Total daily insulin¹, U kg⁻¹ day⁻¹         | 0.44 (0.31)             | 0.44 (0.27)          | 0.50 (0.40)     | 0.002   | 10.9                      | 115, 9.5, 12.2           |
| Use of adjuvant glycaemic therapy, no.     | 8 (1.0%)                | 34 (4.2%)            | 83 (16.6%)      | <0.001  | 0                         |                          |
| Use of statin therapy, no                  | 251 (30.2%)             | 346 (42.2%)          | 289 (57.8%)     | <0.001  | 0                         |                          |
| Hba₁c, mmol mol⁻¹                           | 69.9 (19.0)             | 67.5 (16.4)          | 70.1 (16.2)     | 0.006   | 2.0                       | 2.4, 2.0, 1.6            |
| Hba₁c, %                                   | 8.5 (1.7)               | 8.3 (1.5)            | 8.6 (1.5)       | 0.006   | 2.0                       | 2.4, 2.0, 1.6            |
| Total cholesterol, mmol L⁻¹                | 4.51 (0.86)             | 4.57 (1.03)          | 4.57 (0.98)     | 0.487   | 18.9                      | 18.9, 19.5, 18.0         |
| LDL-c, mmol L⁻¹                            | 2.25 (0.71)             | 2.40 (0.78)          | 2.41 (0.83)     | 0.004   | 46.9                      | 48.0, 45.3, 47.6         |
| HDL-c, mmol L⁻¹                            | 1.78 (0.54)             | 1.61 (0.54)          | 1.63 (1.16)     | <0.001  | 37.9                      | 39.5, 36.1, 38.0         |
| Triglycerides, mmol L⁻¹                    | 1.13 (0.82)             | 1.27 (0.79)          | 1.57 (0.97)     | <0.001  | 33.1                      | 33.2, 32.4, 34.4         |
| Creatinine, mmol L⁻¹                       | 73.6 (47.0)             | 78.1 (61.3)          | 80.6 (62.4)     | 0.085   | 9.7                       | 9.3, 11.0, 8.4           |
| Urine ACR¹                                 | 6.1 (36.2)              | 4.9 (39.9)           | 6.4 (22.1)      | 0.808   | 39.0                      | 36.8, 39.6, 41.8         |

(Continues)
eGDR and the presence of nephropathy. After adjusting for age, gender and duration of diabetes, this strong relationship persisted (adjusted OR 1.98, 3.82 and 8.35 for eGDR 6–7.9, 4–5.9 and <4 mg kg\(^{-1}\) min\(^{-1}\), respectively; \(p < 0.05\) for all) (Figure 3) as it did when adjusting for therapeutic agents other than insulin (adjusted OR 1.71, 2.64 and 5.56 for eGDR 6–7.9, 4–5.9 and <4 mg kg\(^{-1}\) min\(^{-1}\); \(p = 0.07, 0.001\) and <0.001, respectively) (Table S1).

### 3.1.3 | Macrovascular complications

In an unadjusted model, differences in rates of cardiovascular events were seen in those whom were obese (crude OR 1.88 [95% CI: 1.14–3.11; \(p = 0.01\)]) but not in those whom were overweight (\(p = 0.75\)). However, the association found in obese individuals showed only a trend after adjusting for age, gender, HbA\(_1c\) and diabetes duration (adjusted OR 1.66 [95% CI: 0.97–2.86; \(p = 0.07\)]) (Figure 2).

Lower eGDR, on the other hand, was markedly associated with the presence of macrovascular disease in the unadjusted model. After adjustment for age, gender and duration of diabetes, adjusted OR for eGDR <4 mg kg\(^{-1}\) min\(^{-1}\) remained highly significant (adjusted OR 13.22 [95% CI: 3.10–56.38; \(p < 0.001\)]) and a similar pattern was seen for those with eGDR 4–5.9 mg kg\(^{-1}\) min\(^{-1}\) (adjusted OR 6.57 [95% CI: 1.54–28.00; \(p = 0.01\)]) (Figure 3). Even after further adjustment for therapies other than insulin, the

| Patient characteristic | Normal weight (\(n = 832\)) | Overweight (\(n = 819\)) | Obese (\(n = 500\)) | \(p\) value | Missing data in total (%) | Missing data by group (%) |
|------------------------|-----------------------------|--------------------------|---------------------|------------|--------------------------|--------------------------|
| ALT, U L\(^{-1}\)      | 20.7 (12.6)                 | 22.6 (16.5)              | 26.1 (16.7)         | <0.001     | 23.5                     | 23.3, 24.4, 22.4         |
| Retinopathy >grade 1, no | 144 (17.3%)                 | 176 (21.5%)              | 139 (27.8%)         | <0.001     | 0                        |                          |
| Nephropathy, no.       | 80 (15.9%)                  | 80 (16.6%)               | 77 (26.6%)          | <0.001     | 40.7                     | 39.5, 41.0, 42.0         |
| Cardiovascular disease, no | 31 (3.7%)                  | 33 (4.0%)                | 34 (6.8%)           | 0.022      | 0                        |                          |

Abbreviations: ACR, albumin: creatinine ratio; ALT, alanine aminotransferase; BMI, body mass index; CSII, continuous subcutaneous insulin injection; DBP, diastolic blood pressure; eGDR, estimated glucose disposal rate; eGFR, estimated glomerular filtration rate; HDL-c, high-density lipoprotein cholesterol; HTN, hypertension; LDL-c, low-density lipoprotein cholesterol; MDI, multiple daily dose insulin; SBP, systolic blood pressure.

FIGURE 1 Patient enrolment and reasons for exclusion
association between cardiovascular events and those with eGDR < 4 mg kg\(^{-1}\) min\(^{-1}\) remained significant (adjusted OR 5.87 [95% CI: 1.21–28.50; \(p = 0.03\)]) (Table S1).

### 3.2 | Obesity, IR and metabolic parameters

In overweight and obese individuals, systolic and diastolic blood pressures were significantly higher when compared to normal weight patients (Table 1). These differences remained significant after adjusting for age, sex, duration of diabetes and HbA\(_{1c}\) as well as use of antihypertensive agents (Figure S1). HbA\(_{1c}\) in normal weight, overweight and obese individuals were 69.9 ± 19.0, 67.5 ± 16.4 and 70.1 ± 16.2 mmol mol\(^{-1}\), respectively (post-hoc Bonferroni, \(p = 0.16\) for normal weight vs. overweight and \(p = 0.27\) for obese vs. overweight). Total daily insulin requirement in normal weight, overweight and obese individuals were 0.44 ± 0.31, 0.44 ± 0.27 and 0.50 ± 0.40 U kg\(^{-1}\) day\(^{-1}\), respectively (\(p = 0.002\)).

Obese individuals were found to have adverse lipid profiles compared to normal weight patients including an increase in total cholesterol, triglycerides and LDL-cholesterol together with a decrease in HDL-cholesterol. The estimated mean difference of each lipid parameter remained significant after adjusting for age, gender, HbA\(_{1c}\), duration of diabetes and statins (\(p = 0.03\) for total cholesterol, and \(p < 0.001\) for other lipid parameters). The effect of IR (assessed by eGDR category) on lipid parameters resembled that of obesity, whereby individuals with lower eGDR had less desirable lipid profile including higher levels of total cholesterol, triglyceride and LDL-cholesterol as well as lower levels of HDL-cholesterol (Figure S2).

### 3.3 | Use of hypoglycaemic therapies other than insulin

Of the 125 individuals receiving adjuvant anti-hyperglycaemic therapy, 113 individuals were taking Metformin/Metformin modified release, 1 patient received a sodium glucose co-transporter-2 (SGLT2) inhibitor, and 11 individuals were prescribed glucagon-like peptide-1 receptor agonist (GLP1-RA).

Patients receiving adjuvant hypoglycaemic therapies were older (47.5 ± 16.3 vs. 43.2 ± 16.6; \(p = 0.005\)), yet had a trend towards shorter duration of type 1 diabetes (20.1 ± 12.2 vs. 22.2 ± 14.5; \(p = 0.072\)) with a female predominance (female 64% vs. male 36%; \(p < 0.001\)). The odds ratio (OR) for receiving adjuvant anti-hyperglycaemic therapy was significantly higher in both overweight (OR 4.85, 95% CI: 2.22–10.60, \(p < 0.001\)) and obese individuals (OR 21.09, 95% CI: 10.02–44.38, \(p < 0.001\)) compared to healthy weight patients after adjusting for age, gender, HbA\(_{1c}\) and duration of diabetes.

### 3.4 | The relative contribution of HbA\(_{1c}\) and eGDR components to diabetes-related complications

We further evaluated the association of diabetes-related complications and eGDR in the context of various levels of HbA\(_{1c}\). Individuals with the highest eGDR category (≥8 mg kg\(^{-1}\) min\(^{-1}\)) had the lowest complication rates regardless of HbA\(_{1c}\) levels (Figure 4), indicating that HbA\(_{1c}\) is not the sole predictor of microvascular and macrovascular complications in people with type 1 diabetes. The highest complication rate was demonstrated in those with low eGDR and high HbA\(_{1c}\). We also analysed the association between

| Complication/prevalence | Category | \(n\) | Crude OR [95%CI] | \(p\)-value | Adjusted OR* [95%CI] | \(p\)-value |
|--------------------------|----------|------|------------------|------------|-----------------------|------------|
| Retinopathy 456/2,142 (21.3%) | Normal weight | 811 | ref. | | | |
| Overweight | 799 | 1.302 [1.017, 1.667] | 0.036 | 1.347 [1.035, 1.753] | 0.027 |
| Obese | 488 | 1.802 [1.377, 2.357] | <0.001 | 1.643 [1.235, 2.188] | 0.001 |
| Nephropathy 233/1,269 (18.4%) | Normal weight | 499 | ref. | | | |
| Overweight | 479 | 1.066 [0.758, 1.500] | 0.714 | 1.062 [0.733, 1.539] | 0.750 |
| Obese | 285 | 1.928 [1.348, 2.756] | <0.001 | 1.621 [1.100, 2.389] | 0.015 |
| Cardiovascular 98/2,142 (4.6%) | Normal weight | 811 | ref. | | | |
| Overweight | 799 | 1.084 [0.657, 1.788] | 0.752 | 0.990 [0.572, 1.713] | 0.972 |
| Obese | 488 | 1.884 [1.143, 3.108] | 0.013 | 1.664 [0.967, 2.863] | 0.066 |

FIGURE 2 Multiple logistic regression analysis showing odd ratio [95% CI] of retinopathy (>R1), nephropathy and cardiovascular disease by BMI category. †Adjusted for age, sex, diabetes duration and HbA\(_{1c}\). BMI, body mass index.
components of eGDR and complications with results demonstrating that eGDR as a whole shows the strongest association with complications (Table S2).

4 | DISCUSSION

This study aimed to explore the clinical impact of obesity and IR on metabolic parameters and prevalence of vascular complications in people living with type 1 diabetes.

Glycaemic control, measured as HbA1c, is a key predictor of future microvascular disease in individuals with type 1 diabetes. However, we found that BMI may also determine predisposition to microvascular complications, particularly in relation to retinopathy, suggesting that weight also has a role. However, the association between BMI and microvascular disease was relatively modest. In contrast, eGDR showed a stronger association with microvascular disease even after correcting for age and diabetes duration. These findings indicate that microvascular disease in type 1 diabetes is not only modulated by glycaemic control but also IR. Moreover, our data demonstrate that eGDR is more strongly linked to the development of microvascular complications than BMI.

A largely similar pattern was observed for macrovascular disease; obese individuals had increased prevalence of cardiovascular disease but the association between BMI and macrovascular complications lost significance after adjusting for relevant confounders. On the other hand, eGDR was associated with the presence of macrovascular disease with or without adjustment for confounders. It should be noted that previous work has shown a J-shaped or U-shaped association between BMI and mortality in type 1 diabetes individuals.28
which may have played a role in the stronger association of eGDR with complications in our study. However, this J-like effect of BMI would have been minimised in the current work by excluding individual with BMI<18 kg m⁻² from the study.

The relationship between IR, measured as eGDR, and presence of both microvascular and macrovascular complications in this work is well-aligned with previous studies in this area. Advantages of our study include the contemporary and relatively large cohort of patients analysed as well as the in-depth investigation of eGDR and its metabolic components. Overall, our data suggest that eGDR measurement can be useful clinically to further help stratify risk of complications in people with type 1 diabetes. Indeed, a recent nation-wide prospective study from Sweden, including 17,050 individuals with type 1 diabetes, demonstrated an inverse correlation between eGDR and both cardiovascular and all-cause mortality over a 7.1-year follow-up period. This study also showed that survival in individuals with eGDR ≥ 8 mg kg⁻¹ min⁻¹ was similar to people without diabetes. In keeping with this, we found that those with eGDR ≥8 mg kg⁻¹ min⁻¹ had the lowest prevalence of macrovascular complications. The same also applied to microvascular disease, suggesting that eGDR may also be a useful marker to predict the development of these complications.

Just like HbA1c, a key advantage of eGDR is the continuous nature of this variable, making assessment of future vascular risk relatively simple. Unlike HbA1c however, eGDR includes other key measures that are implicated in vascular pathology and influenced by IR. Therefore, eGDR is an IR marker that helps to better stratify the risk of diabetes complications in those with type 1 diabetes than separately using each of its components. Taken together, a reduction in HbA1c may seem protective but this is not necessarily the case if the drop in HbA1c is associated with a significant decrease in eGDR (and hence an increase in IR). In support of this, our data show that high HbA1c per se was not associated with complications in the presence of high eGDR. In contrast, the combination of high HbA1c and low eGDR showed clear associations with complications, emphasising the importance of IR in predisposition to microvascular and macrovascular disease.

Future prospective studies are required to answer a number of clinically relevant questions, including (1) what is the optimal cut-off of eGDR that should be implemented in routine clinical practice? (2) what are the best management strategies to modify eGDR and crucially, (3) is eGDR a measure that people with type 1 diabetes connect to and understand? While a multifactorial intervention in type 1 diabetes is routine practice, this is not always the case in the younger age group where the focus is on glycaemia. Incorporating eGDR into routine practice may help healthcare professionals and patients appreciate the importance of risk factors other than glucose levels, potentially improving long-term outcome in people with type 1 diabetes, particularly those whom are insulin resistant. Also, this will potentially help to explore the effects of adjuvant therapies such as SGLT2 inhibitors and GLP1-RA on the development of complications by monitoring changes in eGDR. A large proportion of patients were overweight/obese in our study but there was relatively little use of adjunctive glycaemic therapies (other than metformin), despite data showing weight loss and/or glycaemic improvement with GLP-1RA and sGLT2 inhibitors.

This study has several strengths. First, it was conducted with real-world data and using a contemporary cohort of patients, reflecting routine clinical practice and making results more generalisable. Second, it is a single-centre study with uniform data collection and relatively large sample size. Third, there was a good spread of ages with high rate of microvascular complications, consistent with the real-world nature of the data. Finally, our results show that eGDR is a strong marker of both microvascular and macrovascular complications, suggesting it can be used to predict risk and monitor response to a specific management strategy.

There are several limitations to this work. First, data were collected using a cross-sectional study design, which can only establish associations and is unable to demonstrate a causal relationship. Second, data analysis employed different adjustments for BMI and eGDR but this is due to the inability to adjust for components of eGDR. Also, caution should be exercised with data interpretation given testing for associations on multiple covariates and the use of a number of models. Third, information on current/previous smoking was lacking and as such we were unable to ascertain if there was any pattern in smoking habits observed and thus were unable to adjust for this important confounder. Fourth, the limited ethnic diversity of the group studied makes generalisability of the results questionable and larger studies involving multiple centres and different countries are warranted to fully understand the potential role of eGDR in routine clinical practice. Fifth, the validity of eGDR in conditions associated with changes in HbA1c, such as haemoglobinopathies and advanced renal failure, remains unknown. Finally, it is important to note that not all studies have found strong correlation between IR determined by clamp techniques and eGDR. However, eGDR correlates well with diabetes complications and as such it has the potential to serve as a vascular risk marker, and future longitudinal studies are required to investigate this possibility.

In conclusion, this study, in a contemporary group of people with type 1 diabetes, shows that eGDR is strongly associated with the presence of both microvascular and macrovascular complications, regardless of HbA1c. This indicates that eGDR may be a useful adjunct marker for risk stratification in routine practice. Future prospective studies are warranted to evaluate the role of modulating eGDR in preventing vascular complications in people with type 1 diabetes, which
will help to fully establish the role of this variable in daily clinical management of type 1 diabetes.

ACKNOWLEDGEMENT
No specific funding was used for collection of data and analysis of results for this study. NK is funded by the Faculty of Medicine, Prince of Songkla University, Thailand.

CONFLICT OF INTEREST
None to declare in relation to this work (all authors).

AUTHORS’ CONTRIBUTION
Harriet Warnes and Rebecca Helliwell collected the majority for data for the study. Noppadol Kietsiriroje and Rebecca Birch performed the statistical analysis and were involved in manuscript creation. Matthew Campbell critically appraised the work and was involved in editing of the final manuscript. Sam M. Pearson was involved in data collection, statistical analysis and manuscript creation. Ramzi A. Aajan had overall oversight of the work and formulated the hypothesis for investigation.

ORCID
Sam M. Pearson https://orcid.org/0000-0002-4943-6759

REFERENCES
1. Nice.org.uk. Type 1 diabetes in adults: diagnosis and management 2016. https://www.nice.org.uk/guidance/ng17. Accessed July 1, 2020.
2. Diabetes.org. Statistics about diabetes: American Diabetes Association; 2018. https://www.diabetes.org/resources/statistics/statistics-about-diabetes
3. Nathan DM, Gough S, Lachin J, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
4. American DA. 6. Glycemic targets: standards of medical care in diabetes—2020. Diabetes Care. 2019;43:S66-S76.
5. Edgerton DS, Moore MC, Winnick JJ, et al. Changes in glucose and fat metabolism in response to the administration of a hepato-preferential insulin analog. Diabetes. 2014;63:3946-3954.
6. Hother-Nielsen O, Schmitz O, Bak J, Beck-Nielsen H. Enhanced hepatic insulin sensitivity, but peripheral insulin resistance in patients with type 1 (insulin-dependent) diabetes. Diabetologia. 1987;30:834-840.
7. Donga E, Dekkers OM, Corrsmit EP, Romijn JA. Insulin resistance in patients with type 1 diabetes assessed by glucose clamp studies: systematic review and meta-analysis. Eur J Endocrinol. 2015;173:101-109.
8. Purnell JQ, Hokanson JE, Marcovina SM, Steffes MW, Cleary PA, Brunzell JD. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes control and complications trial. JAMA. 1998;280:140-146.
9. Lucidi P, Rossetti P, Porcellati F, et al. Mechanisms of insulin resistance after insulin-induced hypoglycemia in humans: the role of lipolysis. Diabetes. 2010;59:1349-1357.
10. Yusuf S, Hawken S, Ounpuu S, et al. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet. 2005;5:1640-1649.
11. Ellulu MS, Patimah I, Khaza’ai H, Rahmat A, Abed Y. Obesity and inflammation: the linking mechanism and the complications. Arch Med Sci. 2017;4:851-863.
12. Lee B-C, Lee J. Cellular and molecular players in adipose tissue inflammation in the development of obesity-induced insulin resistance. Biochem Biophys Acta. 2014;1842:446-462.
13. Kietsiriroje N, Pearson S, Campbell M, Ariëns RAS, Aajan RA. Double diabetes: a distinct high-risk group? Diabetes Obes Metab. 2019;21:2609-2618.
14. Teupe B, Bergis K. Epidemiological evidence for "double diabetes". Lancet. 1991;337:361-362.
15. Thorn LM, Forsblom C, Waden J, et al. Effect of parental type 2 diabetes on offspring with type 1 diabetes. Diabetes Care. 2009;32:63-68.
16. Soedamah-Muthu SS, Chaturvedi N, Witte DR, et al. Relationship between risk factors and mortality in type 1 diabetic patients in Europe: the EURODIAB Prospective Complications Study (PCS). Diabetes Care. 2008;31:1360-1366.
17. Williams KV, Erbey JR, Becker D, Arslanian S, Orchard T. Can clinical factors estimate insulin resistance in type 1 diabetes? Diabetes. 2000;49:626-632.
18. Epstein EJ, Osman JL, Cohen HW, Rajpathak SN, Lewis O, Crandall JP. Use of the estimated glucose disposal rate as a measure of insulin resistance in an urban multiethnic population with type 1 diabetes. Diabetes Care. 2013;36:2280-2285.
19. Nystrom T, Holzmann MJ, Eliasson B, Svensson AM, Sartipy U. Estimated glucose disposal rate predicts mortality in adults with type 1 diabetes. Diabetes Obes Metab. 2018;20:556-563.
20. Pambianco G, Costacou T, Orchard T. The prediction of major outcomes of type 1 diabetes: a 12-year prospective evaluation of three separate definitions of the metabolic syndrome and their components and estimated glucose disposal rate: the Pittsburgh Epidemiology of Diabetes Complications Study experience. Diabetes Care. 2007;30:1248-1254.
21. Simoniene D, Platukiene A, Prakapenke E, Radzveiciene L, Velickiene D. Insulin resistance in type 1 diabetes mellitus and its association with patient's micro- and macrovascular complications, sex hormones, and other clinical data. Diabetes Ther. 2020;11:161-174.
22. Llauradó G, Cano A, Hernández C, et al. Type 1 diabetes: developing the first risk-estimation model for predicting silent myocardial ischemia. The potential role of insulin resistance. PLoS One. 2017;12:e0174640.
23. Orchard TJ, Olson JC, Erbey JR, et al. Insulin resistance-related factors, but not glycemia, predict coronary artery disease in type 1 diabetes: 10-year follow-up data from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care. 2003;26:1374-1379.
24. Orchard TJ, Chang YF, Ferrell RE, Petro N, Ellis DE. Nephropathy in type 1 diabetes: a manifestation of insulin resistance and multiple genetic susceptibilities? Further evidence from the Pittsburgh Epidemiology of Diabetes Complication Study. Kidney Int. 2002;62:963-970.
25. Olson JC, Erbey JR, Forrest KY, Williams K, Becker DJ, Orchard TJ. Glycemia (or, in women, estimated glucose disposal rate) predict lower extremity arterial disease events in type 1 diabetes. *Metab Clin Exp*. 2002;51:248-254.

26. Kilpatrick ES, Rigby AS, Atkin SL. Insulin resistance, the metabolic syndrome, and complication risk in type 1 diabetes: “double diabetes” in the Diabetes Control and Complications Trial. *Diabetes Care*. 2007;30:707-712.

27. Nystrom T, Holzmann MJ, Eliasson B, Svensson AM, Kuhl J, Sartipy U. Estimated glucose disposal rate and long-term survival in type 2 diabetes after coronary artery bypass grafting. *Heart Vessels*. 2017;32:269-278.

28. Dahlström EH, Sandholm N, Forsblom CM, et al. Body mass index and mortality in individuals with type 1 diabetes. *J Clin Endocrinol Metab*. 2019;104:5195-5204.

29. Warnes H, Helliwell R, Pearson SM, Ajjan RA. Metabolic control in type 1 diabetes: is adjunctive therapy the way forward? *Diabetes Ther*. 2018;9:1831-1851.

30. Januszewski AS, Sachithanandan N, Ward G, Karschimkus CS, O’Neal DN, Jenkins AJ. Estimated insulin sensitivity in type 1 diabetes adults using clinical and research biomarkers. *Diabetes Res Clin Pract*. 2020;167:108359.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section.

**How to cite this article:** Helliwell R, Warnes H, Kietsiriroje N, et al. Body mass index, estimated glucose disposal rate and vascular complications in type 1 diabetes: Beyond glycated haemoglobin. *Diabet Med*. 2021;38:e14529. [https://doi.org/10.1111/dme.14529](https://doi.org/10.1111/dme.14529)